Review
Copyright ©The Author(s) 2018.
World J Diabetes. Sep 15, 2018; 9(9): 141-148
Published online Sep 15, 2018. doi: 10.4239/wjd.v9.i9.141
Table 1 Antidiabetic drug and their effect on epicardial adipose tissue
Antidiabetic drugEffect on epicardial adipose tissue
BiguanidesNo effect/Possible synergistic effect with DPP-4 and/or GLP-1[39,40]
Alpha-Glucosidase InhibitorsLack of data concerning the effect of this class
ThiazolidinedionesDecreased inflammatory cytokine release and thickness of EAT (pioglitazone) modulation of cellular hormonal profile (rosiglitazone)[49,50]
Dipeptidyl peptidase-4 inhibitorsReduction of EAT thickness (sitagliptin)[39]
Glucagon-like peptide-1 receptor agonistsReduction of EAT thickness (liraglutide and exenatide)[40,60]
Sodium-glucose cotransporter 2 inhibitorsReduction of EAT thickness (luseogliflozin, ipragliflozin, canagliflozin, dapagliflozin) and inflammation (luseogliflozin, ipragliflozin, dapagliflozin)[63-67]